A method of anabolic treatment in humans comprises administering a compound of the following formula: ##SPC1## Wherein R is halosubstituted, nitrosubstituted, or unsubstituted benzyl, R.sup.2 is hydrogen, methyl or carboxy, and R.sup.3 and R.sup.4 are hydrogen, methoxy or nitro. Pharmaceutical compositions are also disclosed.
RELATED APPLICATIONS
This application is a division of co-pending application U.S. Ser. No. 371,560 filed 19 June 1973, now U.S. Pat. No. 3,907,830 which in turn is a continuation-in-part of U.S. Ser. No. 146,773 filed 25 May 1971, (now U.S. Pat. No. 3,833,730).
The invention relates to the inclusion complexes of 7-isopropoxy-isoflavone formed with cyclodextrin or cyclodextrin derivatives as well as to the pharmaceutical compositions containing these inclusion complexes as active ingredient. The invention further relates to the preparation of the new inclusion complexes. The new inclusion complex according to the invention shows higher dissolution and resorption properties as compared to the active ingredient administered per se.
The invention relates to the inclusion complexes of 7-isopropoxy-isoflavon formed with cyclodextrin or cyclodextrin derivatives as well as to the pharmaceutical compositions containing these inclusion complexes as active ingredient. The invention further relates to the preparation of the new inclusion complexes. The new inclusion complex according to the invention shows higher dissolution and resorption properties as compared to the active ingredient administered per se.
The invention relates to a combination useful for the substitution of bone defects having pathologically developed or being artificially established as well as compositions containing these combinations. The combinations of the invention preferably contain in a weight ratio of 1:9 to 9:1, most preferably 1:1 porous hydroxylapatite and/or tricalcium phosphate in relation to 7-isopropoxyisoflavone.
Edible materials including foods, beverages and oral pharmaceuticals are sweetened by the addition of a sweetening amount in the range of from about 0.002% to 1% by weight (basis edible material) of flavanone represented by the structural formula ##STR1## wherein R is a lower alkyl of from one to three carbon atoms inclusive, n is an integer of from one to three inclusive and M is hydrogen or a physiologically acceptable metal cation.
Substituted 2-vinyl chromones are disclosed, wherein the chromone ring has an alkyl or alkenyl substituent at the 3-position, and a styryl substituent at the 2-position. The compounds exhibit anti-allergy activity and can be used to treat allergic conditions.
